东非和尼日利亚前瞻性队列研究中人类免疫缺陷病毒(HIV)感染者全因死亡率的预测因素
在非洲队列研究(AFRICOS)中,2013至2020年肯尼亚、乌干达、坦桑尼亚和尼日利亚12个站点2724名HIV感染者(98.3%有抗逆转录病毒治疗(ART)经验)的死亡率为11.42/1000人年(95%CI 9.53-13.68)。死亡原因中恶性肿瘤占28.1%、感染占29.7%。CD4≤350细胞/µL、病毒载量每增加1 log10拷贝/mL、近期发热、体重指数<18.5 kg/m2、临床抑郁、WHO III期、血红蛋白每升高1 g/dL及ART每增加一年均与死亡率相关。
要点
- 该队列HIV感染者死亡率为11.42/1000人年(95%CI 9.53-13.68)。
- CD4≤350细胞/µL者死亡风险aHR 2.01(95%CI 1.31-3.08)。
- 病毒载量每增加1 log10拷贝/mL,死亡风险aHR 1.36(95%CI 1.22-1.51)。
核心结论
- 在该主要为病毒抑制的HIV感染者队列中死亡率较低,死亡模式和已识别的预测因素提示减少死亡的多重干预靶点。
研究设计与样本
- 非洲队列研究(AFRICOS)为前瞻性队列,在肯尼亚、乌干达、坦桑尼亚和尼日利亚12个站点纳入伴或不伴HIV的参与者,每6个月评估社会行为问卷、病史、体格检查和实验室检测。
- 2013年至2020年,2724名HIV感染者完成至少1次随访或发生死亡,其中58.4%为女性,25.8%年龄≥50岁,98.3%有ART经验。
- 采用多变量Cox比例风险模型计算调整风险比(aHR)和95%置信区间(CI)。
主要发现
- 死亡率为11.42/1000人年(95%CI 9.53-13.68),54%的参与者死因明确。
- 死因为恶性肿瘤(28.1%)、感染(29.7%)和其他非HIV相关疾病。
- CD4≤350细胞/µL者死亡风险aHR 2.01(95%CI 1.31-3.08),病毒载量每增加1 log10拷贝/mL的aHR 1.36(95%CI 1.22-1.51)。
- 近期发热aHR 1.85(95%CI 1.22-2.81),体重指数<18.5 kg/m2的aHR 2.20(95%CI 1.44-3.38),临床抑郁aHR 2.42(95%CI 1.40-4.18),WHO III期aHR 2.18(95%CI 1.31-3.61)。
- 血红蛋白每升高1 g/dL的aHR 0.79(95%CI 0.72-0.85),ART每增加一年的aHR 0.67(95%CI 0.56-0.81)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Introduction of antiretroviral therapy (ART) has been associated with a decline in human immunodeficiency virus (HIV)-related mortality, although HIV remains a leading cause of death in sub-Saharan Africa. We describe all-cause mortality and its predictors in people living with HIV (PLWH) in the African Cohort Study (AFRICOS). METHODS: AFRICOS enrolls participants with or without HIV at 12 sites in Kenya, Uganda, Tanzania, and Nigeria. Evaluations every 6 months include sociobehavioral questionnaires, medical history, physical examination, and laboratory tests. Mortality data are collected from medical records and survivor interviews. Multivariable Cox proportional hazards models were used to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for factors associated with mortality. RESULTS: From 2013 through 2020, 2724 PLWH completed at least 1 follow-up visit or experienced death. Of these 58.4% were females, 25.8% were aged ≥ 50 years, and 98.3% were ART-experienced. We observed 11.42 deaths per 1000 person-years (95% CI: 9.53-13.68) with causes ascertained in 54% of participants. Deaths were caused by malignancy (28.1%), infections (29.7%), and other non-HIV related conditions. Predictors of mortality included CD4 ≤ 350 cells/µL (aHR 2.01 [95% CI: 1.31-3.08]), a log10copies/mL increase of viral load (aHR 1.36 [95% CI: 1.22-1.51]), recent fever (aHR 1.85[95% CI: 1.22-2.81]), body mass index < 18.5 kg/m2 (aHR 2.20 [95% CI: 1.44-3.38]), clinical depression (aHR 2.42 [95% CI: 1.40-4.18]), World Health Organization (WHO) stage III (aHR 2.18 [95% CI: 1.31-3.61]), a g/dL increase in hemoglobin (aHR 0.79 [95% CI: .72-.85]), and every year on ART (aHR 0.67 [95% CI: .56-.81]). CONCLUSIONS: The mortality rate was low in this cohort of mostly virally suppressed PLWH. Patterns of deaths and identified predictors suggest multiple targets for interventions to reduce mortality.
引用
- Kibuuka H, Musingye E, Mwesigwa B, et al. Predictors of All-Cause Mortality Among People With Human Immunodeficiency Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria. Clin Infect Dis. 2022. PMID: 34864933. doi:10.1093/cid/ciab995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。